🔴 Analysis of biotech with great potentialIn this post I analyzed one interesting biotech Endo International.
Endo is a global pharmaceutical corporation headquartered in Dublin (legal) and Malvern, PA (operating). It was created in 1997 on a joint basis with DuPont Merck. Among the areas of drug development: immunotherapy, dermatology, infectious diseases, insomnia, orthopedics, urology, cellulite, oncology, endocrinology. The company also manufactures pain relievers and equipment needed to diagnose various diseases. Revenue for 2020 is $ 2.9 billion, profit is $ 0.25 million. Capitalization is $ 1.4 billion. Employees 3172.
The company's business is represented by 4 areas:
1. Endo Pharmaceuticals develops unique products from scratch. At the moment, this direction has 16 commercial drugs. There are only 2 drugs in development.
2. Par Pharmaceuticals produces generic (copies) pharmaceuticals. This company was acquired by the American company Endo Pharmaceuticals in 2015 for $ 8.05 billion. This deal allowed Endo to become one of the five largest manufacturers of generics in the United States. Par Pharmaceuticals manufactures about 140 drugs.
3. Endo Aesthetics develops solutions for the treatment of cellulite.
4. Paladin Labs specializes in the acquisition and licensing of new pharmaceutical products for the Canadian market, and also manufactures products for the treatment of allergies, urological and dermatological diseases, diseases of the central nervous system and women's health. The company was acquired by Endo Pharmaceuticals in 2013 for $ 1.6 billion to gain access to the Canadian market and expand into emerging markets.
Endo reached its peak value in 2015, then $ 90 was given per share. This was followed by a collapse in prices amid accusations of the "opioid epidemic" that began in the United States in the late 90s and lasted until 2016. This term refers to a large number of abuse and fatal overdoses of drugs that contain opiates.
Authorities estimate that more than 450,000 Americans have died from opioids in 17 years. Purdue Pharma was identified as the main culprit. However, lawsuits were brought against other corporations as well. Endo has been identified as one of the culprits in the epidemic in 3 states: Ohio, Missouri and Mississippi. In 2016, most of the company's revenues were generated precisely from the sale of opioid-based painkillers.
On November 2, an Orange County Supreme Court judge issued a preliminary ruling that relieves the company of responsibility for fueling the opioid epidemic in the United States. On this day, quotes added almost 10%.
In 2020, Endo, for the first time in many years, made a profit of $ 184 million. Prior to that, for several years in a row, it managed to reduce losses, which in 2017 exceeded $ 2 billion. In general, the company's revenue is stagnating, the company is teetering on the brink of break-even.
An interesting fact: the company for 30 quarters in a row manages to show financial indicators better than analysts' forecasts (in the pharmaceutical industry this is rarely seen).
On November 4, the report for the third quarter was released. The published figures significantly exceeded analysts' estimates. On November 5, quotes added 25%.
🔧In terms of technique, the graph looks towards the short:
1) The price approached a strong weekly level.
2) Closing of the daily and weekly candles near the level and under the very LOW.
3) The price has broken the local level of $ 6.24
4) There is a large power reserve at the bottom.
5) Pulling the local maximum to the level, they are not allowed to go up.
6) Accumulation before the level.
7) Parabolic rounding.
8) Recoilless movement over 250%.
Breakout of the local level $ 6.14
The price is likely to consolidate in the $ 6.15 - $ 6.50 channel with false breakouts of the support level before starting a correction. Be careful.
Goal 1: $ 5.3
Target 2 (risk): $ 3.5 (more than 40% of the movement)
NOT IRR.
Biotech
$PROGProgenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. It offers Innatal, a noninvasive prenatal screening test offered to women early in pregnancy to screen for chromosome abnormalities, such as down syndrome, trisomy 18, trisomy 13, and sex chromosome disorders through the analysis of cell-free DNA; Preparent that screens for carrier status of hereditary diseases prior to or early in pregnancy; and Riscover, a hereditary cancer screen that analyzes 31 genes associated with inherited risk of 12 types of cancers, including the BRCA1/2 genes for hereditary breast, ovarian, colorectal, endometrial, pancreatic, and other cancer syndromes, as well as for the five genes associated with Lynch syndrome. The company also provides Resura, a noninvasive prenatal test for families at risk for rare single gene disorders; and Preecludia, a preeclampsia rule-out test. In addition, it offers anatomic and molecular pathology tests, and COVID-19 PCR testing services, as well as test products that includes chromosomal microarray for pregnancy loss, which evaluates the genetic cause of miscarriage; maternal serum screening for chromosomal disorders; and preimplantation genetic testing for use with artificial reproductive technologies. Further, the company develops therapeutic solutions for gastrointestinal-related disorders, such as PGN-001, PGN-300, PGN-600, and PGN-OB2. It also owns and operates laboratory. Progenity, Inc. was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.
$LGVNLongeveron Inc., a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications comprising aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
$KZR Long term PT 35 and higherKezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and autoimmunity. The company was founded in 2015 and is based in South San Francisco, California.
Novavax LongStrong support line on 122.12$. Firs target on 160$, second - 206$. Stop Limit on 118$. P/L ratio 1:1 for firs target & 3:1.
$MIRM november update*This is not financial advice, so trade at your own risks*
*My team digs deep and finds stocks that are expected to perform well based off multiple confluences*
*Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management*
Recap: My team entered $MIRM on 10/29/21 at $15.70 per share. Our first take profit is at $26.
Mirum Pharmaceuticals $MIRM released their 3rd quarter earnings today after market close. In this report they announced a loss of -$1.55 per share on revenue of $5.0 million. This earnings beat is staggering, especially when acknowledging the fact that the revenue consensus was only $0.8 million. $MIRM is still an under the radar company currently, but a revenue beat of 502.4% will definitely turn some heads. In addition, post-earnings five insiders accumulated a vast amount of shares. These insiders know what's coming, and lucky for us we do too. Our first take profit is honestly a huge underestimate of this companies potential, and in the future we may have to make some major adjustments.
This is a buy and throw away the key type of investment. My teams holding! Will you?
OUR ENTRY: $15.70
FIRST TAKE PROFIT: $26
If you want to see more, please like and follow us @SimplyShowMeTheMoney
Possibly the most undervalued stock on the TSX!- $19M mkt cap / 11M float
- $28.4M cash eq.
- $17.1M Q3 revenue / $7M adjusted EBITDA
- Options at $3.27
- Warrants at $3.53
- Enterprise value (as of Sep 30, 2021): $103.8M!!
- Canadian Commercial business is focused on Pain, Neurology, Allergy, And Dermatology therapeutics.
- 17 Global Distribution Partners across 31 Countries.
- Over 100 global patents and patent applications
- 20+ products, 7 proprietary products, ~ 100 employees
$CERE: Blue Skies for This $PFE spinoff?This recent $PFE spinoff who went public via SPAC in 2020 could be a strong portfolio holding in the months and years to come. Experienced leadership taking on the unique challenge of solving a lot of the mental health issues that could very well be leading to the tight labor markets we've witnessed recently.
TARGET HIT $PFR 9.05% in 14 days TARGET HIT $PFR 9.05% in 14 days
Wooo hoooo…. Great game!!!
Definitely room for this to go higher...
——————
I am not your financial advisor, but I will happily answer questions and analyze to the best of my ability but ultimately the risk is on you. Check out my ideas, but also do your own due diligence.
If you want me to analyze any stock or ETF just leave me a comment and I’ll do it if I can.
Have fun, y’all!!
(\_/)
( •_•)
/ >🚀
$INSP: Sleep Apnea TreatmentsINSP changing the sleep apnea world with their revolutionary new minimally invasive treatment, potentially taking lion's share from other companies who manufacture CPAP machines. Good luck traders!
$ZNTL: Oncology MomentumZNTL broke 80 again today and is displaying a strong monthly momentum chart. IBB regaining 160 hopefully will signal at least a moderate health care push that could push ZNTL into the 90s and beyond. Good luck traders!
BNGO ready for a breakout?Bionano Genomics, it is in the field of gene sequencing.
The company`s product, Saphyr, uses optical genome mapping to help detect structural variations in gene sequencing.
Bionano recently acquired BioDiscovery for $100 million, which is a leader in clinical software production.
The acquisition may facilitate adoption of the Saphyr system, in $4 billion market segment.
I see a strong support at this level and an upside, according to BTIG Research of $10 per share.
AZYO HOLDING SUPPORT - INSANE LOW FLOAT 2M SHARESAll,
Almost worth a buy and super tight stop loss here just to see what happens if this breaks and holds this support. Could be an easy return. I don't see much risk here just put a very tight stop loss -6%ish whatever you R/T is.
PTSI - WW - CLOSE TO BREAKING - LOW FLOAT 28MAll,
PTSI looks ready break here. Being biotech did not look into when news should be released based on various drugs etc they do. TA wise it is definitely ready or near ready. Set some alerts and I would watch this daily possibly for next week or so.
As any Bio company all news moves the stock and the float helps. It's almost like magic when they release news when TA is setup at the same time lol. Just watch it.
LFMD - SHORT TERM OPTIONS PLAY - GAP + ERAll,
I think LFMD has a shot here to at least fill the gap and go a little further 6.50-7.00 range with that being said I am only interested in short term options with tight stop losses or a longer term $10 call way out. Most analysts put this around $16 range. I think it's a little lower maybe $10-$12.
MUST add tight stop loss on options or stock here. The downside to this stock would plummet if it lost another level of support.
Possible Wykoff accum. after price discovery - NUMI shroomboomNUMI could be in the midst of a Wykoff accumulation.
^ means a pro, v means a con.
I am trying to look at both sides to reduce emotionally-blinded decision making.
Looking from far, there is systematic market risk:
v institutions adopting Bitcoin, resulting in broad market exposure to USDT fraud risk and Bitcoin volatility
v GME apes stressing underlying system
A broader market pullback or turn to bear market can affect any stock's price.
Looking at the sector:
^ I believe I know that psychedelics work, and are safe
^ mental health a huge industry that impacts all sectors because..humans, and looks to grow due to COVID
v proper testing can take time and money
v Canadian election can affect the path the sector takes.
I believe the psychedelics market is in the nascent stages of a multi-year bull market. Valuing companies in the sector right now is difficult.
Looking at the company:
^ one of the few companies in the sector that actually has revenue
^ lower risk of `going to zero` because not focused on novel compounds
^ is focused on creating IP
v lower potential to moon because not focused on patenting compounds
v rank-ordered within industry, less focused on making money, more focused on helping people and making help accessible
^ outstanding team and network
^ focused on psychedelic-assisted psychotherapy (similar to shamanic-assisted tripping, which is an ancient, proven methodology)
^ $63.2 million cash position (1/3 current market value @~$0.87
^ YOY revenue is expected to increase by ~100%
v not much attention on reddit (hey, it seems to matter)
^ lower volatility due to lack of meme-retail involvement
v has diluted shares in the past
The company is solid, growing through acquisitions and research, and a leader in the sector.
Numinus is licence by Health Canada to cultivate, extract and sell psychedelic compounds. They also have a dealer's licence to import, export, possess, test and distribute MDMA, psilocybin, psilocin, DMT and mescaline.
v my understanding is that ibogaine is the most effective psychedelic specifically for opioid addiction. but entails cardiac risk, but numinus does not seem to be working with ibogaine-derived compounds
The book: Bear Market Trading Strategies by Matthew R Kratter say that if a stock moves above it's 200 day MA, one can consider shorting. Playing with this logic, NUMI is below it's 200 day MA in what looks to be a possible multi-year bull market, so now might be a good entry point.
On morality and ethics:
Numinus may not have a 1B valuation like MMED (with 0 revenue), but by supporting a company that is focused on natural healing and accessibility it is a step in a direction away from the big pharma method of `extracting value from` towards the team human (podcast) method of `creating value for`. And I believe that is what the mushrooms want :).
How does investing help Numinus Wellness:
A higher stock price allows for things such as uplisting to the TSX and NYSE which gives them more access to capital. Also, investor support allows them to obtain capital at a higher valuation.
Full disclosure:
I bought NUMI at 28c, have sold off portions several time for a variety of reasons, and now am dollar cost averaging in again during sideways movement and am focusing on managing risk.
This is my first chart publish. I will appreciate all feedback, critical or otherwise.
This is not financial advice.
$PFE - Key Levels and Analysis$PFE - Key Levels and Analysis
So it looks like It might be time to start a position in PFE…
Target 45.92, or double position at 38.30
@Smartdaytrading I’m not sure if you saw this since the last post, its right at that projected buy level.
This is definitely on my radar for tomorrow.
——————
I am not your financial advisor, but I will happily answer questions and analyze to the best of my ability but ultimately the risk is on you. Check out my ideas, but also do your due diligence.
If you want me to analyze any stock or ETF just leave me a comment and I’ll do it if I can.
Have fun, y’all!!
BABA - HUGE OPTIONS PLAY - FALLING WEDGE + CHANNELAll,
BABA is PRIMED here. Just a question of has it hit bottom. I would wait for break or daily candles conformation personally, but then i'd be all in here. This should break the falling wedge and hit the top of the downtrend channel. Huge plays here. This should take more of your attention than any small cap etc stocks. Make sure to set many alerts on this. Telling you this is worth big returns could see 180-200 by end of 2021. Especially holidays nearing etc.
SPRB - 8M FLOAT - WORTH X2-X3 CURRENT PRICEAll,
I am already scaled in big here. I am without a doubt this stock will at least double.
***KEEP IN MIND THIS IS AN 8M FLOAT COMPANY
1. Do your own DD you will notice all that has really happened is low float short sellers have just railed the price down
2. This companies price targets are insane not to mention 8M float will make this EXPLODE on any good news. The company is already undervalued + postiive news of any kind just blows this baby to the moon. Except here the moon is probably where it SHOULD be.
3. Financially speaking easily in great position no chance of offerings
4. Promising company overall
5. This downtrend looks awful, but is purely short sellers and look at the length of the time on market.
This looks like it may happen soon, but either way I will happily add large position scales into this stock and simply wait. I really think at some point even a year from now we see 20+. The question is do you want to chase stocks daily, weekly or scale in. Either way set alers and volume alerts.
ADMA - OBVIOUS BUY DUHHHAll,
Just look at larger timeframes and price targets + last two EPS. I'm going in with 5% stop loss here. No reason not to. Undervalued, float is mediocre nothing great, but absolutely worth a stab here.
$BHVN: BullhavenWith an increasingly strong dollar and crude oil prices on the move there's some belief the Fed could need to move faster on rate hikes than previously planned. This should be a net positive for BHVN assuming. Were hoping most of the rout from XLV and IBB will clear soon against the backdrop of a strong dollar.
The biotech era possibilities: reverse aging, cure cancer, ...A little intro to the biotech cycle... It could be real big.
RNA technology can do a little bit more than tell your genes to produce spike protein.
It could be used to fight cancer.
It could also be used to increase life expectancy from 75 years to perhaps 90.
And more importantly, make people age slower as well as kill "deficient" cells involved in aging.
This means "prime" and "old age" would go from 25-50 and 50-75 to 25-60 and 60-90. Can you imagine?
Of course this is not eternal life, but us humans prime for what seems like such a short time, especially as our life expectancy increase.
You get to 25 and it's a race. By 50 it's over. At 35 you're already basically halfway through and missed on so much prossibly.
But if you got until 60 then it would make a significant difference. You life would not be "over" just a few years after reaching adulthood.
A while ago they came up with solutions but they had a little downside: it was highly cancerigenous.
Research has improved, and if people don't revert to the stone age soon (no guarentee about that), it will continue.
Plenty of treatments (injections, drugs, not RNA modifications) have been tested, and we have seen "70 year old" mice run faster than "25 year olds".
They have been tested on various mammals and plants. And to my knowledge, 1 human. David Sinclair, a genetician that looks at least 10 years younger than he is.
Not going to lie, the first people to get access to this, after the innovators (the few professors testing it on themselves) will be rich people.
Anti-ageing through DNA therapy got to be cheaper and work better than weekly injections of 5 products + 25 other products to counter the side effects.
RNA also is used to fight rare diseases, genetic disorders, but this concerns a tiny part of the population.
It's nice and all, but let's be honest, most people care way more about increasing everyone's (and their) healthy life spans.
Other uses:
Vaccines. Obviously.
Hunger management (you could also just ban obesity like Japan or ban the industry from dumping trucks of sugar and salt in their food to make people hungry).
Faster fracture repair (maybe send gene instructions temporarly)
Cure all sorts of handicaps (up to 10% of the population)
Less very dumb people (that are unemployable)?
Hair loss
Color blindness
Finally fix these teeth constantly getting damaged by bacteria
Regrow an arm?
Some cool sci-fi stuff? X-ray vision maybe?
Idk unlimited possibilities
A huge market bubble since "unlimited possibilities" Oh I can already see it
Right now they are showing the population that RNA tech isn't scary by using them all (most of the pop) as guinea pigs and force vaccinating a lot of people.
But I think they are calming down. These guys aren't that bright but at some point they might figure out if they insist too much they will alienate people and make them ultra-conservative and anti-vaxx and anti-everything. The boomers in power don't have long, so of course they are in a hurry to push this tech at any cost. Funny. They are desperate. The only western president that is young is Macron and OF COURSE his wife is like 80 or something.
The risk is MOAR mass hysteria, MORE euphorism, so I think ultimately people will get greedy and go after more and more half tested rushed treatments, and traders should know the outcome: eventually, a catastrophe. Mass deaths followed by reverting back to ultra conservative values.
Good buy on the next major bear market (this company or whichever one survives). But investing in this is not even the most interesting part.
